Prognostic Role of Fasting Remnant Cholesterol with In-Stent Restenosis After Drug-Eluting Stent Implantation

References

• Khattab MH, Sherry AD, Barker CM. The birth, decline, and contemporary re-emergence of endovascular brachytherapy for prevention of in-stent restenosis. Brachytherapy. 2021;20(2):485–493. doi:10.1016/j.brachy.2020.09.012
   PubMed Web of Science ®Google Scholar
• Singh AD, Singal AK, Mian A, et al. Recurrent drug-eluting stent in-stent restenosis: a state-of-the-art review of pathophysiology, diagnosis, and management. Cardiovasc Revasc Med. 2020;21(9):1157–1163. doi:10.1016/j.carrev.2020.01.005
   PubMed Web of Science ®Google Scholar
• Dangas GD, Claessen BE, Caixeta A, et al. In-stent restenosis in the drug-eluting stent era. J Am Coll Cardiol. 2010;56(23):1897–1907. doi:10.1016/j.jacc.2010.07.028
   PubMed Web of Science ®Google Scholar
• Stolker JM, Cohen DJ, Kennedy KF, et al. Repeat revascularization after contemporary percutaneous coronary intervention: an evaluation of staged, target lesion, and other unplanned revascularization procedures during the first year. Circ Cardiovasc Interv. 2012;5(6):772–782. doi:10.1161/CIRCINTERVENTIONS.111.967802
   PubMed Web of Science ®Google Scholar
• Nakano M, Otsuka F, Yahagi K, et al. Human autopsy study of drug-eluting stents restenosis: histomorphological predictors and neointimal characteristics. Eur Heart J. 2013;34(42):3304–3313. doi:10.1093/eurheartj/eht241
   PubMed Web of Science ®Google Scholar
• Duran EK, Pradhan AD. Triglyceride-rich lipoprotein remnants and cardiovascular disease. Clin Chem. 2021;67(1):183–196. doi:10.1093/clinchem/hvaa296
   PubMed Web of Science ®Google Scholar
• Díaz Rodríguez Á, Mantilla Morató T. LDL as a therapeutic objective. Clin Investig Arterioscler. 2019;31 Suppl 2:1–15. doi:10.1016/j.arteri.2019.10.004
   PubMed Web of Science ®Google Scholar
• Gai M-T, Zhu B, Chen X-C, et al. A prediction model based on platelet parameters, lipid levels, and angiographic characteristics to predict in-stent restenosis in coronary artery disease patients implanted with drug-eluting stents. Lipids Health Dis. 2021;20(1):118. doi:10.1186/s12944-021-01553-2
   PubMed Web of Science ®Google Scholar
• Castañer O, Pintó X, Subirana I, et al. Remnant cholesterol, not LDL cholesterol, is associated with incident cardiovascular disease. J Am Coll Cardiol. 2020;76(23):2712–2724. doi:10.1016/j.jacc.2020.10.008
   PubMed Web of Science ®Google Scholar
• Elshazly MB, Mani P, Nissen S, et al. Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease. Eur J Prev Cardiol. 2020;27(10):1091–1100. doi:10.1177/2047487319887578
   PubMed Web of Science ®Google Scholar
• Chait A, Ginsberg HN, Vaisar T, et al. Remnants of the triglyceride-rich lipoproteins, diabetes, and cardiovascular disease. Diabetes. 2020;69(4):508–516. doi:10.2337/dbi19-0007
   PubMed Web of Science ®Google Scholar
• Burnett JR, Hooper AJ, Hegele RA. Remnant cholesterol and atherosclerotic cardiovascular disease risk. J Am Coll Cardiol. 2020;76(23):2736–2739. doi:10.1016/j.jacc.2020.10.029
   PubMed Web of Science ®Google Scholar
• Bonfiglio C, Leone CM, Silveira LVA, et al. Remnant cholesterol as a risk factor for cardiovascular, cancer or other causes mortality: a competing risks analysis. Nutr Metab Cardiovasc Dis. 2020;30(11):2093–2102. doi:10.1016/j.numecd.2020.07.002
   PubMed Web of Science ®Google Scholar
• Qin Z, Zhou K, Li Y-P, et al. Remnant lipoproteins play an important role of in-stent restenosis in type 2 diabetes undergoing percutaneous coronary intervention: a single-centre observational cohort study. Cardiovasc Diabetol. 2019;18(1):11. doi:10.1186/s12933-019-0819-z
   PubMed Web of Science ®Google Scholar
• Varbo A, Benn M, Smith GD, et al. Remnant cholesterol, low-density lipoprotein cholesterol, and blood pressure as mediators from obesity to ischemic heart disease. Circ Res. 2015;116(4):665–673. doi:10.1161/CIRCRESAHA.116.304846
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Royston P, Binder H. Selection of important variables and determination of functional form for continuous predictors in multivariable model building. Stat Med. 2007;26(30):5512–5528. doi:10.1002/sim.3148
   PubMed Web of Science ®Google Scholar
• Hari P, Khandelwal P, Smoyer WE. Dyslipidemia and cardiovascular health in childhood nephrotic syndrome. Pediatr Nephrol. 2020;35(9):1601–1619. doi:10.1007/s00467-019-04301-y
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2015 ACC/AHA/SCAI focused update on primary percutaneous coronary intervention for patients with ST-elevation myocardial infarction: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention and the 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol. 2016;67(10):1235–1250. doi:10.1016/j.jacc.2015.10.005
   PubMed Web of Science ®Google Scholar
• ESC Committee for Practice Guidelines (CPG). 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Atherosclerosis. 2019;290:140–205. doi:10.1016/j.atherosclerosis.2019.08.014
   PubMed Web of Science ®Google Scholar
• Mach F, Baigent C, Catapano AL. Erratum to “2019 ESC/EAS guidelines for the management of dyslipidemias: lipid modification to reduce cardiovascular risk” [Atherosclerosis 290 (2019) 140-205]. Atherosclerosis. 2020;292(p):160–162. doi:10.1016/j.atherosclerosis.2019.11.020
   PubMed Web of Science ®Google Scholar
• Ray KK, Kastelein JJP, Matthijs Boekholdt S, et al. The ACC/AHA 2013 guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular disease risk in adults: the good the bad and the uncertain: a comparison with ESC/EAS guidelines for the management of dyslipidaemias 2011. Eur Heart J. 2014;35(15):960–968. doi:10.1093/eurheartj/ehu107
   PubMed Web of Science ®Google Scholar
• He W, Xu C, Wang X, et al. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention. BMC Cardiovasc Disord. 2021;21(1):435. doi:10.1186/s12872-021-02255-4
   PubMed Web of Science ®Google Scholar
• Kim C, Kim B-K, Lee S-Y, et al. Incidence, clinical presentation, and predictors of early neoatherosclerosis after drug-eluting stent implantation. Am Heart J. 2015;170(3):591–597. doi:10.1016/j.ahj.2015.06.005
   PubMed Web of Science ®Google Scholar
• Salinas CAA, Chapman MJ. Remnant lipoproteins: are they equal to or more atherogenic than LDL? Curr Opin Lipidol. 2020;31(3):132–139. doi:10.1097/MOL.0000000000000682
   PubMed Web of Science ®Google Scholar
• Varbo A, Freiberg JJ, Nordestgaard BG. Extreme nonfasting remnant cholesterol vs extreme LDL cholesterol as contributors to cardiovascular disease and all-cause mortality in 90000 individuals from the general population. Clin Chem. 2015;61(3):533–543. doi:10.1373/clinchem.2014.234146
   PubMed Web of Science ®Google Scholar
• Varbo A, Langsted A, Nordestgaard BG. Commentary: nonfasting remnant cholesterol simplifies triglyceride-rich lipoproteins for clinical use, and metabolomic phenotyping ignites scientific curiosity. Int J Epidemiol. 2016;45(5):1379–1385. doi:10.1093/ije/dyw215
   PubMed Web of Science ®Google Scholar
• Varbo A, Nordestgaard BG. Remnant cholesterol and risk of ischemic stroke in 112,512 individuals from the general population. Ann Neurol. 2019;85(4):550–559. doi:10.1002/ana.25432
   PubMed Web of Science ®Google Scholar
• Tada H, Nohara A, Inazu A, et al. Remnant lipoproteins and atherosclerotic cardiovascular disease. Clin Chim Acta. 2019;490:1–5. doi:10.1016/j.cca.2018.12.014
   PubMed Web of Science ®Google Scholar
• Yao HM, Wan YD, Zhang XJ, et al. Long-term follow-up results in patients undergoing percutaneous coronary intervention (PCI) with drug-eluting stents: results from a single high-volume PCI centre. BMJ Open. 2014;4(8):e004892. doi:10.1136/bmjopen-2014-004892
   PubMed Web of Science ®Google Scholar